Bioasis Technologies Inc.
BTI
株式のランク
#39864
Bioasis Technologies Inc. is a development-stage biopharmaceutical firm focused... Bioasis Technologies Inc. is a development-stage biopharmaceutical firm focused on innovating diagnostic methods and therapeutic solutions for a range of neurological conditions. The company's primary technological asset is the xB3 platform, engineered to enable the transport of medicinal compounds across the often-impenetrable blood-brain barrier. This capability is crucial for addressing central nervous system disorders, including various brain cancers, metabolic dysfunctions, and neurodegenerative illnesses. Bioasis is actively advancing its in-house pipeline with programs such as xB3-001 for brain metastases, xB3-002 for glioblastoma, and xB3-007 for neurodegenerative diseases, all designed to offer both symptomatic relief and disease-modifying benefits. The company has also established numerous strategic alliances. These include a partnership with Aposense Limited to deliver siRNA therapeutics for CNS disorders; a collaboration with Oxyrane UK Ltd. to combine the xB3 technology with Oxyrane's OxyCAT platform for enhanced enzyme replacement therapy targeting the brain; an agreement with Janssen Biotech, Inc. for the discovery, development, and commercialization of novel products leveraging the xB3 platform; and a research and licensing deal with Neuramedy Co Ltd. to develop and market an xB3-enhanced version of their antibody, Tomaralimab. Founded in 2006, Bioasis Technologies Inc. is headquartered in New Haven, Connecticut.
株価
$0.00366968
最終同期: 2024-07-23
時価総額
$291.42K
変化（1日）
-0.81%
変化（1年）
1,734.84%
国
US
取引 Bioasis Technologies Inc. (BTI)
カテゴリー
Healthcare
の時価総額 Bioasis Technologies Inc.(BTI)
時価総額: $291.42K
October 2026時点で、Bioasis Technologies Inc. の時価総額は $291.42K です。これは、当社のデータによると、Bioasis Technologies Inc. が世界で39864th番目に価値のある企業であることを意味します。時価総額は、上場企業の発行済株式の総市場価値であり、企業の価値を測るためによく使用されます。
Bioasis Technologies Inc. の時価総額の履歴（2010 から 2026 まで）
